These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 10517730)

  • 1. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
    Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
    Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
    Antman EM; Cohen M; Bernink PJ; McCabe CH; Horacek T; Papuchis G; Mautner B; Corbalan R; Radley D; Braunwald E
    JAMA; 2000 Aug; 284(7):835-42. PubMed ID: 10938172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
    Collet JP; Montalescot G; Fine E; Golmard JL; Dalby M; Choussat R; Ankri A; Dumaine R; Lesty C; Vignolles N; Thomas D
    J Am Coll Cardiol; 2003 Jan; 41(1):8-14. PubMed ID: 12570937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
    Antman EM; Cohen M; McCabe C; Goodman SG; Murphy SA; Braunwald E;
    Eur Heart J; 2002 Feb; 23(4):308-14. PubMed ID: 11812067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
    Petersen JL; Mahaffey KW; Hasselblad V; Antman EM; Cohen M; Goodman SG; Langer A; Blazing MA; Le-Moigne-Amrani A; de Lemos JA; Nessel CC; Harrington RA; Ferguson JJ; Braunwald E; Califf RM
    JAMA; 2004 Jul; 292(1):89-96. PubMed ID: 15238596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
    Berkowitz SD; Stinnett S; Cohen M; Fromell GJ; Bigonzi F;
    Am J Cardiol; 2001 Dec; 88(11):1230-4. PubMed ID: 11728348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
    Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
    Cohen M; Antman EM; Gurfinkel EP; Radley D;
    J Thromb Thrombolysis; 2001 Dec; 12(3):199-206. PubMed ID: 11981102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
    Borja J; Olivella P
    Med Clin (Barc); 2000 Nov; 115(15):583-6. PubMed ID: 11141394
    [No Abstract]   [Full Text] [Related]  

  • 18. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction.
    Cohen M
    Semin Thromb Hemost; 1999; 25 Suppl 3():113-21. PubMed ID: 10549726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction.
    Cohen M; Antman EM; Gurfinkel E; Turpie AG; Furst J; Bigonzi F; Radley D
    Am J Cardiol; 2000 Sep; 86(5):553-6, A9. PubMed ID: 11009278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.